First relapse in multiple myeloma: the patient perspective
Insights on Evolving Treatment Strategies for Multiple Myeloma
The panel provides key takeaways on the most impactful innovations shaping the future of multiple myeloma treatment.
Clinical Advice on Caring for Patients Treated With Talquetamab
The panel provides clinical advice on caring for patients with multiple myeloma who are treated with talquetamab.
Integrating GPRC5D-Targeting Bispecifics for Relapsed/Refractory MM
Beth Faiman, PhD, MSN, explores how a GPRC5D-targeting bispecific antibody can benefit patients with relapsed/refractory multiple myeloma.
Managing Toxicities From Talquetamab in Multiple Myeloma
Experts explore strategies to effectively manage toxicities associated with talquetamab in the treatment of multiple myeloma.
Strategies for Discussing Potential Adverse Effects of Talquetamab in MM
Experts discuss best practices for educating patients with multiple myeloma on the adverse effects associated with talquetamab treatment.
Navigating MM Treatment: Sequencing Strategies and Integrating Talquetamab
This session explores clinical evidence for sequencing treatments in MM, highlighting the safety profile of talquetamab as a potential tool in your MM patient management.
Clinical Scenario: Treating Late-Line Relapsed Multiple Myeloma
Following the repeat diagnostic workup presentation, an expert will lead the discussion, inviting the panel's input on the most appropriate treatment course for this patient.
Empowering Patients With Myeloma Through Resources
The panel discussed resources to equip nurses in educating patients with multiple myeloma about their treatment options.
Case Study: 63-Year-Old Man With Multiple Myeloma
A team of multiple myeloma experts review a patient profile, offering preliminary insights and underscoring the importance of advanced practice providers in optimizing patient care.
Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer
Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC
Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer
Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care